ClinicalTrials.gg
CompletedNCT00002140Updated Jun 24, 2005

A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients

A Phase 3 interventional study of Ethambutol hydrochloride and Clarithromycin in Mycobacterium Avium-intracellulare Infection and HIV Infections, sponsored by Pfizer. Completed at 24 sites in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Mycobacterium avium-intracellulare Infection by Pfizer — none open to participants now, none under way, none of them phase 3. Mycobacterium avium-intracellulare Infection · Pfizer.

Phase 3
3 of 12
none open now
Registered
1st of 12
by date

Among the 12 studies in Mycobacterium avium-intracellulare Infection by Pfizer, this one is one of 3 in phase 3, and was the 1st registered.

Mycobacterium avium-intracellulare Infection

66 studies on the registry are indexed under Mycobacterium avium-intracellulare Infection; 8 are open to participants now.

Browse Mycobacterium avium-intracellulare Infection studies →

Open to participants now

None of the 12 studies in Mycobacterium avium-intracellulare Infection by Pfizer is open now. The open studies under Mycobacterium avium-intracellulare Infection, anywhere →

Where they have run

Who these studies take

Of the 7 Mycobacterium avium-intracellulare Infection studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Mycobacterium avium-intracellulare Infection by Pfizer as a file.
02

Study summary

To evaluate the efficacy and safety of two different doses of azithromycin in combination with ethambutol for the treatment of patients with Mycobacterium avium complex (MAC) infection, and to determine whether an azithromycin-containing regimen is at least as safe and effective as the same regimen containing clarithromycin..

Read the detailed description

Patients are randomized to receive azithromycin at one of two doses in combination with ethambutol or clarithromycin in combination with ethambutol for 24 weeks, after which they are evaluated for entry into a maintenance phase of treatment. Clinical, microbiologic, and safety assessments are performed every 3 weeks for the first 12 weeks, then monthly for the remaining 12 weeks.

03

Conditions studied

  • Mycobacterium Avium-intracellulare Infection
  • HIV Infections

Keywords

  • Mycobacterium avium-intracellulare Infection
  • Drug Therapy, Combination
  • Ethambutol
  • Acquired Immunodeficiency Syndrome
  • Azithromycin
  • Clarithromycin
04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must have:

  • seropositivity.
  • Disseminated MAC.
  • No MAC therapy between time of last positive blood culture draw and study entry (single-agent prophylaxis allowed).
  • of at least 2 months.
  • Consent of parent or guardian if below legal age of consent.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Known to macrolide antibiotics (erythromycin, azithromycin, or clarithromycin) or ethambutol.
  • Inability to take oral medications.
  • Condition likely to interfere with drug absorption (e.g., gastrectomy, malabsorption syndromes).

Concurrent Medication:

Excluded:

  • Another drug started in the week prior to study entry.

Prior Medication:

Excluded:

  • MAC therapy between time of last positive blood culture draw and study entry (although single-agent prophylaxis is allowed).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Masking
Double
06

Study locations

24 sites
  • East Bay AIDS Ctr
    Berkeley, California 94705, United States
  • Dr Milton Estes
    Mill Valley, California 94941, United States
  • Infectious Disease Med Group / Adult Immunology Clinic
    Oakland, California 94609, United States
  • UCI Med Ctr
    Orange, California 92668, United States
  • Kaiser Permanente Med Ctr
    San Francisco, California 94115, United States
  • Santa Clara Valley Med Ctr
    San Jose, California 951282699, United States
  • Pfizer Central Research
    Groton, Connecticut 06340, United States
  • Georgetown Univ Med Ctr
    Washington, District of Columbia 20007, United States
  • Whitman - Walker Clinic
    Washington, District of Columbia 20009, United States
  • Med Service
    Miami, Florida 33125, United States
  • Dr Robert Wallace
    St Petersburg, Florida 33713, United States
  • Bay Area AIDS Consortium
    Tampa, Florida 33609, United States
  • West Paces Clinical Research Inc
    Atlanta, Georgia 30327, United States
  • Northwestern Univ Med School
    Chicago, Illinois 60611, United States
  • Dr Neel French / Louis A Weiss Memorial Hosp
    Chicago, Illinois 60640, United States
  • Oschner Clinic
    New Orleans, Louisiana 70121, United States
  • Trinity Lutheran Hosp / Infectious Disease Clinic
    Kansas City, Missouri 64108, United States
  • Duke Univ Med Ctr
    Durham, North Carolina 27710, United States
  • Austin Infectious Disease Consultants
    Austin, Texas 78705, United States
  • Central Texas Med Foundation
    Austin, Texas 78751, United States
  • Univ of Texas Southwestern Med Ctr of Dallas
    Dallas, Texas 75235, United States
  • Thomas Street Clinic / Baylor College of Medicine
    Houston, Texas 77009, United States
  • Dr Gary Brewton
    Houston, Texas 77027, United States
  • Hampton Roads Med Specialists
    Hampton, Virginia 23666, United States
07

References and documents

Publications

  • Dunne M, Fessel J, Kumar P, Dickenson G, Keiser P, Boulos M, Mogyros M, White AC Jr, Cahn P, O'Connor M, Lewi D, Green S, Tilles J, Hicks C, Bissett J, Schneider MM, Benner R. A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Clin Infect Dis. 2000 Nov;31(5):1245-52. doi: 10.1086/317468. Epub 2000 Nov 6. Erratum In: Clin Infect Dis 2001 May 1;32(9):1386. PubMed 11073759 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00002140
Lead sponsor
Pfizer
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 1998. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ethambutol · Clarithromycin · Azithromycin

Start the discussion